English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Malaria is a highly prevalent parasitic disease in regions with tropical and subtropical climates worldwide. Among the species of  Plasmodium  causing human malaria,  P. vivax  is the second most prevalent and the most geographically widespread species. A major target of a pre-erythrocytic vaccine is the  P. vivax  circumsporozoite protein ( Pv CSP). In previous studies, we fused two recombinant proteins representing three allelic variants of  Pv CSP (VK210, VK247 and  P. vivax -like) to the mumps virus nucleocapsid protein to enhance immune responses against  Pv CSP. The objective of the present study was to evaluate the protective efficacy of these recombinants in mice challenged with transgenic  P. berghei  parasites expressing  Pv CSP allelic variants. Formulations containing Poly (I:C) or Montanide ISA720 as adjuvants elicited high and long-lasting IgG antibody titers specific to each  Pv CSP allelic variant. Immunized mice were challenged with two existing chimeric  P. berghei  parasite lines expressing  Pv CSP-VK210 and  Pv CSP-VK247. We also developed a novel chimeric line expressing the third allelic variant,  Pv CSP- P. vivax -like, as a new murine immunization-challenge model. Our formulations conferred partial protection (significant delay in the time to reach 1% parasitemia) against challenge with the three chimeric parasites. Our results provide insights into the development of a vaccine targeting multiple strains of  P. vivax .

A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles